News | Advanced Visualization | May 29, 2018

Technology identifies 8 out of a possible 57 image feature variables that could distinguish benign and malignant tumors

Researchers Use Radiomics to Overcome False Positives in Lung Cancer CT Screening

May 29, 2018 — A team of researchers including investigators from Mayo Clinic has identified a technology to address the problem of false positives in computed tomography (CT)-based lung cancer screening. The team’s findings are published in the current issue of PLOS One.

“As physicians, one of the most challenging problems in screening patients for lung cancer is that the vast majority of the detected pulmonary nodules are not cancer,” said Tobias Peikert, M.D., a pulmonologist at Mayo Clinic. “Even in individuals who are at high risk for lung cancer, up to 96 percent of nodules are not cancer.”

Peikert said false-positive test results cause significant patient anxiety and often lead to unnecessary additional testing, including surgery. “False-positive lung cancer screening results also increase healthcare costs and may lead to unintentional physician-caused injury and mortality,” Peikert said.

To address the problem of false positives in lung cancer screening, Peikert and Fabien Maldonado, M.D., from Vanderbilt University, along with their collaborators, used a radiomics approach to analyze the CT images of all lung cancers diagnosed as part of the National Lung Cancer Screening Trial. Radiomics is a field of medicine that involves extracting large amounts of quantitative data from medical images and using computer programs to identify disease characteristics that cannot be seen by the naked eye.

Researchers tested a set of 57 variables for volume, nodule density, shape, nodule surface characteristics and texture of the surrounding lung tissue. They identified eight variables which enabled them to distinguish a benign nodule from a cancerous nodule. None of the eight variables were directly linked to nodule size and the researchers did not include any demographic variables such as age, smoking status and prior cancer history as part of their testing.

Peikert said that while the technology looks very promising and has the potential to change the way physicians evaluate incidentally detected lung nodules, it still requires additional validation.

Funding for this research was provided by the Department of Defense, in collaboration with Vanderbilt University School of Medicine.

For more information: www.journals.plos.org/plosone

Related Lung Cancer Content

Artificial Intelligence Improves Lung Cancer Detection

ACR Urges Stricter Adherence to Lung Cancer Screening Guidelines


Related Content

News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Ultrasound Imaging

March 2, 2026 — Esaote Group will officially launch the new MyLab E85 and MyLab C30 GTS Edition ultrasound systems at ...

Time March 02, 2026
arrow
News | Remote Viewing Systems

Feb. 26, 2026 — DeepHealth, Inc., a provider of AI-powered health informatics and a wholly owned subsidiary of RadNet ...

Time February 27, 2026
arrow
News | FDA

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the ...

Time February 26, 2026
arrow
News | Digital Pathology

Feb. 11, 2026 — Leica Biosystems has announced the global launch of the Leica CM1950 Cryostat with DualEcoTec Cooling ...

Time February 11, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 9, 2026 — MRIguidance, a MedTech company developing BoneMRI, a radiation-free bone imaging solution, has appointed ...

Time February 09, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
Subscribe Now